CLINICA CAYANGA |
||
|
|
Duloxetine decreases pain of diabetic neuropathy |
|
|
Alzheimer's
Disease Arthritis Asthma Benign Prostatic Hypertrophy Chronic Lymphocytic Leukemia Coronary Artery Disease Depression Diabetes Mellitus Dyspepsia Erectile Dysfunction Fatty Liver Gallstone Hepatitis Hypertension Lung Cancer Mesothelioma Metabolic Syndrome Obesity Pneumonia Pregnancy Prostate Cancer Sinusitis Stroke Tinnitus |
Clinical Question: Does duloxetine reduce pain in patients with diabetic peripheral neuropathy? Bottom Line: This study confirms previous findings that duloxetine at 60 mg QD and 60 mg BID is effective and safe in the management of diabetic peripheral neuropathic pain.Higher doses of duloxetine didn't provide much additional benefit. The biases in this study favor treatment, so it is likely that the real benefit is less than what these investigators observed. Finally, we don't know if duloxetine is any more effective than other treatments used for painful diabetic neuropathy. Reference: Wernicke JF, Pritchett YL, D'Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006;67:1411-1420. Study Design: Randomized controlled trial (double-blinded) Synopsis: Serotonin (5-HT) and norepinephrine (NE) are involved in pain modulation via descending inhibitory pathways in the brain and spinal cord. The authors assess the efficacy of duloxetine, a dual reuptake inhibitor of 5-HT and NE, on the reduction of pain severity, as well as secondary outcome measures in patients with diabetic peripheral neuropathic pain (DPNP). In this double-blind study, patients with DPNP and without comorbid depression were randomly assigned to treatment with duloxetine 60 mg once daily (QD), duloxetine 60 mg twice daily (BID), or placebo for 12 weeks. The primary outcome measure was the weekly mean score of 24-hour average pain severity on the 11-point Likert scale. Secondary measures and health outcome measures were also assessed. Duloxetine 60 mg QD and 60 mg BID demonstrated improvement in the management of DPNP and showed rapid onset of action, with separation from placebo beginning at week 1 on the 24-hour average pain severity score. For all secondary measures for pain (except allodynia), mean changes showed an advantage of duloxetine over placebo, with no significant difference between 60 mg QD and 60 mg BID. Clinical Global Impression of Severity and Patient's Global Impression of Improvement evaluation demonstrated greater improvement on duloxetine- vs placebo-treated patients. Duloxetine showed no notable interference on diabetic controls, and both doses were safely administered. |
|
|
Patient Information |
||
| Health For Life | ||
|
Medical Library |
||
|
Breaking Medical News Clinical Tools Coronary Risk Profile Dermatology Diabetes Corner Evidence-Based Medicine Free Medical Books Free Medical Journal History Taking and Physical Examination Hows on Making Diagnostic Examination Medical Journal (popular) Medical Organizations Medical Professional News Neurological and Psychiatric Problems in Clinical Practice Palm Tools Medical Notes Medical Physiology (Lecture) Medical Resources Medical Search Online Clinical Calculator Scientific Meeting |
||
| Online Sari-Sari Store | ||
Please
support Clinica Cayanga Medical Resources by purchasing gift items
at  |
||
|
Home | Introduction | Scheduling a Visit| Laboratory Work | Reaching Us | Map to our Office | About the Doctors |
||